8-KOther Events

AMGEN INC 8-K Report, Corporate Update (Sep 16, 2008)

Filed September 16, 2008For Securities:AMGN

Summary

Amgen Inc. (AMGN) has filed a Form 8-K to report additional data from its pivotal fracture trial for denosumab, a RANK Ligand inhibitor, in the treatment of postmenopausal osteoporosis. The trial results demonstrate a significant reduction in fracture risk across multiple categories when compared to placebo, offering a potentially strong indication for the drug's efficacy in a key therapeutic area. Key findings show that denosumab significantly reduced the risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over a three-year period. While the overall incidence of adverse events was similar between the denosumab and placebo groups, specific serious adverse events and other reported conditions warrant investor attention. The absence of osteonecrosis of the jaw (ONJ) cases is also a notable point, as this has been a concern with other bone-related therapies.

Key Highlights

  • 1Amgen presented additional data from its pivotal fracture trial for denosumab in postmenopausal osteoporosis.
  • 2Denosumab demonstrated a 68% reduction in the risk of new vertebral fractures versus placebo (P<0.0001).
  • 3Hip fracture risk was reduced by 40% with denosumab treatment (P=0.036).
  • 4Nonvertebral fracture risk saw a 20% reduction with denosumab (P=0.011).
  • 5The trial involved 7,808 women over a three-year period, with denosumab administered as a 60 mg subcutaneous injection every 6 months.
  • 6Adverse event profiles were largely similar between denosumab and placebo groups, with some specific events noted.
  • 7No cases of osteonecrosis of the jaw (ONJ) were observed in either treatment arm.

Frequently Asked Questions

The primary outcome is the significant reduction in fracture risk for postmenopausal women with osteoporosis treated with denosumab compared to placebo. Specifically, denosumab showed substantial efficacy in reducing vertebral, hip, and nonvertebral fractures over a three-year period.

While the overall incidence of adverse events was similar to placebo, investors should note reported infections (both general and serious), delayed fracture healing, stroke, coronary heart disease events, and atrial fibrillation. The company also noted specific events like falls and flatulence. Importantly, no cases of osteonecrosis of the jaw (ONJ) were reported.

These positive results in a large pivotal trial for osteoporosis, a significant and prevalent condition, suggest denosumab has strong potential as a new therapeutic option. Successful regulatory approval and commercialization could lead to substantial revenue for Amgen, particularly given the demonstrated efficacy across multiple fracture types.

Amgen announced that additional data would be presented at the annual meeting of the American Society of Bone and Mineral Research in Montreal, Canada, on September 16, 2008.